Observational Study
Copyright ©The Author(s) 2019.
World J Clin Oncol. Dec 24, 2019; 10(12): 391-401
Published online Dec 24, 2019. doi: 10.5306/wjco.v10.i12.391
Table 1 Clinical and nutritional characteristics of the sample at baseline
Characteristicsn = 22
Age (yr, mean value)61
Weight (kg, mean value ± SD)64 ± 14.2
BMI (mean value ± SD)25 ± 5.2
Allergies, n (%)
Yes15 (68.2)
No7 (31.8)
Smoke, n (%)
Yes5 (22.7)
No17 (77.3)
Alcohol, n (%)
Yes8 (36.4)
No14 (63.6)
Type of gynecological cancer, n (%)
Cervical cancer5 (22.7)
Endometrial cancer2 (9.1)
Ovarian cancer15 (68.2)
Chemotherapy treatment, n (%)
Carboplatin2 (9.2)
Carboplatin - Bevacizumab1 (4.5)
Carboplatin - Caelyx3 (13.6)
Carboplatin - Gemcitabine2 (9.2)
Carboplatin - Taxol9 (40.9)
Carboplatin - Gemcitabine - Bevacizumab1 (4.5)
Cisplatin3 (13.6)
Cisplatin – Bevacizumab1 (4.5)
Number of lines, n (%)
I14 (63.6)
II7 (31.8)
III1 (4.6)
Nutritional requirements
BEE in kcal (Average value ± SD)1262.5 ± 146.6
TEE in kcal (Average value ± SD)1678.9 ± 177.1
Mediterranean diet adherence
MDSS (mean value ± SD)12.5 ± 3.4
MDSS ≥ 13, n (%)12 (54.5)
MDSS < 1310 (45.5)
Table 2 Anthropometric and nutritional characteristics of the two groups at the baseline according to the Mediterranean diet adherence score
MDSS ≥ 13
MDSS < 13
Total
(n = 12)(n = 10)(n = 22)
Age (yr, mean value ± SD)64.9 ± 11.656.4 ± 11.961 ± 12.2
Weight (kg, mean value ± SD)61.3 ± 11.467.2 ± 1764 ± 14.2
BMI (mean value ± SD)24.5 ± 4.325.7 ± 6.325 ± 5.2
MDSS (mean value ± SD)15.1 ± 2.19.5 ± 1.712.5 ± 3.4
Average daily intake
Proteins (g, mean value ± SD)67.8 ± 15.683.5 ± 3274.9 ± 25.1
Fats (g, mean value ± SD)73.7 ± 21.991.6 ± 41.281.8 ± 32.6
Saturated fats (g, mean value ± SD)25.8 ± 7.433.1 ± 19.929.1 ± 14.6
Carbohydrates (g, mean value ± SD)227.5 ± 37.7208.3 ± 80218.8 ± 59.8
Sugars (g, mean value ± SD)91 ± 1585,9 ± 2988,7 ± 22
Fibers (g, mean value ± SD)22 ± 4.517.3 ± 619.9 ± 5.6
Energy intake (kcal, mean value ± SD)1893.3 ± 376.32038.7 ± 724.81959.4 ± 552.1
Fluid intake (mL, mean value ± SD)1320.8 ± 491.51365 ± 7041340.9 ± 582.6
Coverage of the TEE (mean % ± SD)115.8 ± 20.2117.7 ± 41.6116.7 ± 30.9
Coverage of the TEE > 100%, n (%)10 (83.3)5 (50)15 (68.2)
Table 3 Nutritional-anthropometric features derived from the analysis of the second food frequency questionnaire
MDSS ≥ 13
MDSS < 13
Total
(n = 12)( n = 10)( n = 22)
Weight (kg, mean value ± SD)61 ± 11.367.2 ± 17.363.8 ± 14.3
BMI (mean value ± SD)24.4 ± 4.325.7 ± 6.325 ± 5.2
MDSS (mean value ± SD)13.3 ± 0.88.9 ± 2.611.3 ± 2.9
Average daily intake
Proteins (g, mean value ± SD)56.1 ± 15.570.6 ± 34.262.7 ± 26.1
Fats (g, mean value ± SD)60.6 ± 17.883 ± 2970.8 ± 25.6
Saturated fats (g, mean value ± SD)21.3 ± 6.627.5 ± 1224.1 ± 9.7
Carbohydrates (g, mean value ± SD)212.5 ± 55.9215 ± 95.6213.6 ± 74.5
Sugars (g, mean value ± SD)87.9 ± 20.699 ± 37.993 ± 29.5
Fibers (g, mean value ± SD)18.3 ± 5.518.7 ± 8.318.5 ± 6.8
Energy intake (kcal, mean value ± SD)1633.8 ± 406.81921.7 ± 687.71764.6 ± 557.5
Fluid intake (mL, mean value ± SD)1400 ± 495.51388.9 ± 416.71394.7 ± 427.5
Coverage of the TEE (%, mean value ± SD)100.2 ± 24.5110.4 ± 36.4104.8 ± 30.1
Coverage of the TEE > 100%, n (%)7 (58.3)5 (50)12 (54.5)
Table 4 Gastrointestinal toxicities’ score after first chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13MDSS < 13TotalP value
Dry mouth (G)1 ± 1.31.1 ± 1.31 ± 1.30.85
Dysphagia (G)0.3 ± 0.50.4 ± 0.70.3 ± 0.60.70
Oral sores (A)0.2 ± 0.40.5 ± 1.30.3 ± 0.90.45
Oral sores (G)0.1 ± 0.30.4 ± 1.30.2 ± 0.90.44
Mouth’s cracks (G)0.1 ± 0.30.4 ± 1.30.2 ± 0.90.44
Dysgeusia (G)0.9 ± 1.21 ± 1.21 ± 1.20.84
Loss of appetite (I.A)1.1 ± 1.11.4 ± 1.51.2 ± 1.30.59
Loss of appetite (G)1 ± 11.3 ± 1.71.1 ± 1.30.61
Nausea (F)1.5 ± 1.11.4 ± 1.61.5 ± 1.30.86
Nausea (G)1 ± 0.91.5 ± 1.71.2 ±1.30.38
Vomiting (F)0.6 ± 0.80.6 ± 1.30.6 ± 11
Vomiting (G)0.3 ± 0.50.6 ± 1.30.5 ± 10.46
Stomachache (F)0.2 ± 0.60.7 ± 0.90.4 ± 0.80.13
Stomachache (G)0.1 ± 0.30.5 ± 0.70.3 ± 0.60.08
Intestinal gas (yes/no)0.4 ± 0.50.3 ± 0.50.4 ± 0.50.64
Bloating (F)0.7 ± 0.90.5 ± 10.6 ± 0.90.62
Bloating (G)0.3 ± 0.50.4 ± 0.70.4 ± 0.60.70
Constipation (G)0.5 ± 0.50.7 ± 0.70.6 ± 0.60.44
Diarrhea (F)0.7 ± 0.90.7 ± 1.30.7 ± 1.11
Abdomen ache (F)1.1 ± 10.3 ± 0.70.7 ± 0.90.04
Abdomen ache (G)0.8 ± 0.80.2 ± 0.40.5 ± 0.70.04
Abdomen ache (I.A)0.7 ± 0.80.2 ± 0.60.5 ± 0.70.11
Toxicity (TOT)13.4 ± 6.615.1 ± 14.514.2 ± 10.70.7
Table 5 Gastrointestinal toxicities’ score after last chemotherapy cycle in the whole study population and in the two study’s groups according to the Mediterranean diet serving score
MDSS ≥ 13MDSS < 13TotalP value
Dry mouth (G)1.5 ± 1.80.8 ± 1.81.2 ± 1.70.53
Dysphagia (G)0 ± 00.2 ± 0.40.1 ± 0.30.24
Oral sores (G)0 ± 00 ± 00 ± 01
Oral sores (A)0 ± 00 ± 00 ± 01
Mouth’s cracks (G)0 ± 00.2 ± 0.40.1 ± 0.30.24
Dysgeusia (G)1.3 ± 1.52.6 ± 1.91.9 ± 1.80.23
Loss of appetite (G)1.3 ± 1.52.4 ± 1.71.8 ± 1.60.28
Loss of appetite (I.A)1.3 ± 1.52 ± 1.41.6 ± 1.40.44
Nausea (F)0.7 ± 1.63.6 ± 0.92 ± 2< 0.01
Nausea (G)0.7 ± 1.63.4 ± 0.91.9 ± 1.9< 0.01
Vomiting (F)0.3 ± 0.80.8 ± 1.30.5 ± 10.45
Vomiting (G)0.2 ± 0.41 ± 1.70.5 ± 1.20.28
Stomach ache (F)0 ± 01 ± 10.5 ± 0.80.03
Stomach ache (G)0 ± 01.2 ± 1.30.5 ± 10.04
Gas (yes/no)0.3 ± 0.50.4 ± 0.50.4 ± 0.50.74
Bloating (F)0 ± 01.4 ± 1.30.6 ± 1.10.02
Bloating (G)0 ± 01 ± 10.5 ± 0.80.03
Constipation (G)0.8 ± 0.42.4 ± 1.81.5 ± 1.40.06
Diarrhea (F)0.5 ± 0.81.2 ± 1.10.8 ± 10.25
Abdomen ache (F)0.2 ± 0.41.4 ± 0.90.7 ± 0.90.01
Abdomen ache (G)0.2 ± 0.41.2 ± 0.80.6 ± 0.80.02
Abdomen ache (I.A)0.2 ± 0.41.2 ± 0.80.6 ± 0.80.02
GI toxicity (TOT)9.5 ± 10.929.4 ± 10.418.5 ± 14.50.01